Uterotonic Drugs for the Prevention of Postpartum Haemorrhage: A Cost-Effectiveness Analysis

Karen Pickering, Ioannis D. Gallos, Helen Williams, Malcolm J. Price, Abi Merriel, David Lissauer, Aurelio Tobias, G. Justus Hofmeyr, Arri Coomarasamy and Tracy E. Roberts ()
Additional contact information
Karen Pickering: University of Birmingham
Ioannis D. Gallos: University of Birmingham
Helen Williams: University of Birmingham
Malcolm J. Price: University of Birmingham
Abi Merriel: University of Birmingham
David Lissauer: University of Birmingham
Aurelio Tobias: University of Birmingham
G. Justus Hofmeyr: University of Fort Hare, Eastern Cape Department of Health
Arri Coomarasamy: University of Birmingham
Tracy E. Roberts: University of Birmingham

PharmacoEconomics - Open, 2019, vol. 3, issue 2, No 5, 163-176

Abstract: Abstract Objective The objective of this study was to estimate the relative cost effectiveness for the full range of uterotonic drugs available for preventing postpartum haemorrhage (PPH). Methods A model-based economic evaluation was constructed using effectiveness data from a network meta-analysis, and supplemented by the literature. A UK National Health Service (NHS) perspective was adopted for the analysis, which is based on UK costs from published sources. The primary outcome measure is cost per case of PPH avoided (≥ 500 mL blood loss), with secondary outcome measures of cost per case of severe PPH avoided (≥ 1000 mL) and cost per major outcome (surgery) averted also being analysed. Results Carbetocin is shown to be the most effective strategy. Excluding adverse events, ‘ergometrine plus oxytocin’ was shown to be the least costly strategy. The incremental cost-effectiveness ratio for prevention of PPH with carbetocin compared with prevention with ‘ergometrine plus oxytocin’ was £1889 per case of PPH ≥ 500 mL avoided; £30,013 per case of PPH ≥ 1000 mL avoided; and £1,172,378 per major outcome averted. Including adverse events in the analysis showed oxytocin to be the least costly strategy. The incremental cost-effectiveness ratio for prevention of PPH with carbetocin compared with prevention with oxytocin was £928 per case of PPH ≥ 500 mL avoided; £22,900 per case of PPH ≥ 1000 mL avoided; and £894,514 per major outcome averted. Conclusion The results suggest carbetocin, oxytocin and ‘ergometrine plus oxytocin’ could all be favourable options for being the most cost-effective strategy for preventing PPH. Carbetocin could be the preferred choice, especially if the price of carbetocin decreased. Mixed findings mean a clear-cut conclusion cannot be made as to which uterotonic is the most cost effective. Future research should focus on collecting more robust evidence on the probability of having adverse events from the uterotonic drugs, and on adapting the model for low- and middle-income countries.

Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-018-0108-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:3:y:2019:i:2:d:10.1007_s41669-018-0108-x

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-018-0108-x

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().